Optimizing Analytical Technologies & Approaches to Characterization, Standardization, Quality & Potency to Permit Efficient Release & Commercial Approval of mRNA Medicines
August 27th - 29th, 2024 | Berlin, Germany
2nd mRNA Analytical Development Summit Europe
Empowering Innovation in Highly Precise, Sensitive & Robust mRNA Analytical Development
With continued pressure on drug development timelines paired with a lack of regulatory guidance, the demand for innovative, efficient, and high-throughput analytical methods is crucial to ensure the approval and successful commercialization of safe and effective mRNA therapeutics and vaccines.
As such, the highly anticipated 2nd mRNA Analytical Development Summit Europe 2024 returns to Berlin as the premier gathering for industry professionals to delve into optimized mRNA analytics. Join us to gain critical expertise and hear the latest techniques adopted by Europe's leading biopharma leaders.
Reuniting 80+ industry experts in Analytical Development, Quality Control, Quality Assurance, CMC, and Regulatory, this forum aims to tackle pivotal challenges within mRNA analytical development including mRNA quality and purification, as well as navigating issues surrounding heterogeneity, encapsulation, and nanoparticle biodistribution.
Across this comprehensive 3-day forum, we foster a collaborative community of like-minded experts from across Europe. Prepare to engage in dynamic discussions, gain invaluable insights, and forge meaningful connections that propel the field of mRNA therapeutics and vaccines forward.
At this leading forum, industry experts will navigate through case-study-led presentations & interactive discussions to:
Uncover Innovative Strategies to Maximise mRNA Characterisation to Ensure Safety, Efficacy & Quality of mRNA Therapeutics & Vaccines
Delve into Standards & Regulatory Requirements for the Analytical Development of mRNA Vaccines for Rapid Approvals & Commercial Readiness
Optimize mRNA Delivery Systems & LNP Payload Analysis to Improve Stability & Efficiency of Your mRNA Therapeutics & Address Hurdles in Targeted Delivery